Patents Issued in November 9, 2017
  • Publication number: 20170319577
    Abstract: Disclosed are compositions for the treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is acetyl-para-aminophenol (APAP) that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic and nociceptive pain.
    Type: Application
    Filed: July 17, 2017
    Publication date: November 9, 2017
    Inventor: Annette Channa Toledano
  • Publication number: 20170319578
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 9, 2017
    Inventors: Gabor Csjernyik, Sofia Karlstrom, Annika Kers, Karin Kolmodin, Martin Nylof, Liselotte Ohberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Soderman, Britt-Marie Swahn, Stefan Von Berg
  • Publication number: 20170319579
    Abstract: Methods and compositions for reducing frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.
    Type: Application
    Filed: July 6, 2017
    Publication date: November 9, 2017
    Inventor: David A. DILL
  • Publication number: 20170319580
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 9, 2017
    Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • Publication number: 20170319581
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Applicant: Merck Patent GmbH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • Publication number: 20170319582
    Abstract: Therapeutic methods, kits, dosing regimens and uses as medicament are provided, for example, for the treatment of bacterial infection. The therapeutic methods can comprise intravenously administering to a subject who has a bacterial infection a pharmaceutical composition comprising a fixed amount of iclaprim. The administration of the fixed amount can achieve a Cmax(ss) below about 800 ng/mL, a T>MIC of between about 30% to about 95% and a ratio of AUC/MIC of about 20 to about 85, and the bacterial infection can be treated. The fixed amount can be about 70 mg to about 100 mg. The pharmaceutical composition can be infused into the subject about 1 to about 3 times a day daily over a time period of about 0.75 hours to about 4 hours.
    Type: Application
    Filed: May 3, 2017
    Publication date: November 9, 2017
    Inventors: David Huang, Keith A. Bostian, William G. Kramer
  • Publication number: 20170319583
    Abstract: Therapeutic methods, kits, dosing regimens and uses of a medicament comprising iclaprim are provided, for example, for the treatment of bacterial infection. The administration of iclaprim in a fixed amount can achieve a Cmax(ss) below about 800 ng/mL, a T>MIC of between about 30% to about 95% and a ratio of AUC/MIC of about 20 to about 85, and the bacterial infection can be treated. The fixed amount can be about 70 mg to about 100 mg. The bacterial infection treated may be caused, or related to, drug-resistant bacteria including S. pneumoniae, H. influenzae, S. aureus, K. pneumoniae and M. catarrhalis. The bacterial infection may manifest as a skin and skin structure infection, pneumonia, asthma, emphysema and/or other adverse pulmonary conditions.
    Type: Application
    Filed: May 4, 2017
    Publication date: November 9, 2017
    Inventor: David Huang
  • Publication number: 20170319584
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventors: Andrew WASMUTH, Donald W. LANDRY, Shi Xian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
  • Publication number: 20170319585
    Abstract: Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells.
    Type: Application
    Filed: March 27, 2015
    Publication date: November 9, 2017
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Yingjuan June Lu, Kevin Yu Wang, Fei Yu, Paul Joseph Kleindl, Hari Krishna R. Santhapuram
  • Publication number: 20170319586
    Abstract: The present invention relates to pharmaceutical compositions containing a combination of reduced forms of folate, liver protectors, vitamins, and essential or non-essential amino acids, useful in preventing the adverse effects associated with prolonged use of dihydrofolate reductase inhibitors.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 9, 2017
    Inventors: Julio César Villamil Torres, Camilo Rey Ferro
  • Publication number: 20170319587
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Application
    Filed: June 19, 2017
    Publication date: November 9, 2017
    Applicant: Oncoceutics, Inc.
    Inventors: Martin STOGNIEW, Joshua E. ALLEN
  • Publication number: 20170319588
    Abstract: The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.
    Type: Application
    Filed: July 12, 2017
    Publication date: November 9, 2017
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazumichi JO, Hideki TAKEUCHI
  • Publication number: 20170319589
    Abstract: The present invention provides methods and compositions JUT. treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal foliate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 9, 2017
    Inventor: Linzy O. Scott, III
  • Publication number: 20170319590
    Abstract: The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.
    Type: Application
    Filed: June 12, 2017
    Publication date: November 9, 2017
    Inventors: Matthew J. Buderer, Dennis Saadeh, Andrew R. Boll
  • Publication number: 20170319591
    Abstract: Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, ?-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from an ERK inhibitor, a MEK inhibitor, and, a Raf inhibitor. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells are also provided.
    Type: Application
    Filed: February 9, 2017
    Publication date: November 9, 2017
    Applicant: DUKE UNIVERSITY
    Inventor: Rahima Zennadi
  • Publication number: 20170319592
    Abstract: The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.
    Type: Application
    Filed: November 3, 2015
    Publication date: November 9, 2017
    Inventors: SEOK GOO CHO, KEON-Il IM, JUNG YEON LIM, NAYOUN KIM, YOUNG SUN NAM, EUN SOL LEE
  • Publication number: 20170319593
    Abstract: The invention relates to a 7-aminocephalosporanic acid derivative, Cefazolin, for use as an inhibitor of IL-15 and IL-2 receptors in the prevention and treatment of diseases related to IL-15 and IL-2 overproduction.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventors: Katarzyna Koziak, Barbara Zyzynska-Granica, Slawomir Filipek, Szymon Niewieczerzal, Bartosz Trzaskowski, Oliwia Zegrocka-Stendel, Malgorzata Dutkiewicz, Piotr Krzeczynski, Elzbieta Kaczmarek, Magdalena Winiarska
  • Publication number: 20170319594
    Abstract: The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
    Type: Application
    Filed: July 26, 2017
    Publication date: November 9, 2017
    Inventors: Jean-Christophe CARRY, Fabienne CHATREAUX, Stephanie DEPRETS, Olivier DUCLOS, Vincent LEROY, Sergio MALLART, Dominique MELON-MANGUER, Maria MENDEZ-PEREZ, Fabrice VERGNE
  • Publication number: 20170319595
    Abstract: The invention relates to the field of metal-organic framework materials and the field of medical technology, relates to a method for inhibiting tumor angiogenesis or preventing and/or treating tumor, comprising administering to a subject in need thereof an effective amount of a metal-organic framework comprising Fe and ligand. The invention further relates to a method for inhibiting the expression of matrix metalloproteinase in a cell, comprising administering to the cell an effective amount of a metal-organic framework comprising Fe and ligand.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 9, 2017
    Applicant: Yunnan University
    Inventors: Bin Li, Daomei Chen, Jiaqiang Wang, Minfang Nie
  • Publication number: 20170319596
    Abstract: This application relates to methods and compositions useful for improving quality of life, sexual domain function or a combination thereof.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 9, 2017
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Nachaegari
  • Publication number: 20170319597
    Abstract: The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
    Type: Application
    Filed: April 18, 2017
    Publication date: November 9, 2017
    Inventor: Stephen Nigel Birrell
  • Publication number: 20170319598
    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.
    Type: Application
    Filed: November 24, 2015
    Publication date: November 9, 2017
    Applicant: TROPHEA DEVELOPMENT AB
    Inventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
  • Publication number: 20170319599
    Abstract: Provided is a means with which it is possible to efficiently prevent or improve symptoms caused by an imbalance of sex hormones with as little pain as possible, and which can safely be taken daily. A compound selected from the group consisting of a lophenol compound and a cyclolanostane compound is used as an active ingredient of an agent for preventing or improving symptoms caused by an imbalance of sex hormones.
    Type: Application
    Filed: November 27, 2015
    Publication date: November 9, 2017
    Inventors: Eriko MISAWA, Ruiqing YAO, Marie SAITO, Miyuki TANAKA
  • Publication number: 20170319600
    Abstract: Provided is a matrix metalloproteinase production inhibitor which can be daily taken safely. In the matrix metalloproteinase production inhibitor, a compound selected from the group consisting of a lophenol compound and a cyclolanostane compound is used as an active ingredient.
    Type: Application
    Filed: November 27, 2015
    Publication date: November 9, 2017
    Inventors: Marie SAITO, Eriko MISAWA, Miyuki TANAKA, Ruiqing YAO
  • Publication number: 20170319601
    Abstract: This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 9, 2017
    Applicant: Kythera Biopharmaceuticals, Inc.
    Inventor: Patricia Walker
  • Publication number: 20170319602
    Abstract: Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 9, 2017
    Inventors: Kevin Peters, Robert Shalwitz
  • Publication number: 20170319603
    Abstract: Methods of treating or preventing a C. difficile infection and the associated pathological conditions related to C. difficile infection, are disclosed.
    Type: Application
    Filed: March 24, 2017
    Publication date: November 9, 2017
    Inventors: S. Ken Tanaka, Michael P. Draper
  • Publication number: 20170319604
    Abstract: A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.
    Type: Application
    Filed: April 20, 2017
    Publication date: November 9, 2017
    Inventors: Mark Erion, Hongjian Jiang, Serge Henri Boyer
  • Publication number: 20170319605
    Abstract: The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ri is selected from an SCN— group or is an RCONH— group; in particular, where Ri=RCONH, R is selected from an aromatic benzene ring substituted with an SCN— group in the ortho, meta or para position, according to the following formula: SCN— or R is a C1-C4 alkyl chain, substituted with an SCN— group; n can be equal to 0 or else 1.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 9, 2017
    Applicants: ISTITUTO ORTOPEDICO RIZZOLI, UNIVERSITA' DI PISA
    Inventors: Gina Lisignoli, Francesco Grassi, Vincenzo Calderone, Simona Rapposelli
  • Publication number: 20170319606
    Abstract: The invention relates to hydrosoluble hydroxybisphosphonic derivatives of doxorubicin of formula (I) and the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compounds as a drug, especially in the treatment of a bone tumour. The invention further relates to the pharmaceutical compositions comprising such compounds, the methods for the synthesis thereof and synthesis intermediates.
    Type: Application
    Filed: November 20, 2015
    Publication date: November 9, 2017
    Applicant: Atlanthera
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot, Emmanuelle David
  • Publication number: 20170319607
    Abstract: This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.
    Type: Application
    Filed: July 11, 2017
    Publication date: November 9, 2017
    Applicant: BODYBIO INC.
    Inventors: EDWARD KANE, PATRICIA KANE, BRETT T. HAUSER
  • Publication number: 20170319608
    Abstract: Composition, preferably, in the form of capsules or chewable wafers in quantities suitable for relieving the symptoms of fibromyalgia comprise formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients are described.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventor: Robert A. Settineri
  • Publication number: 20170319609
    Abstract: Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of “warhead” anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compositions comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, undesirable fibrosis, and undesirable inflammation.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 9, 2017
    Inventors: William W. Bachovchin, Hung-sen Lai, David G. Sanford, Sarah E. Poplawski, Wengen Wu
  • Publication number: 20170319610
    Abstract: This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.
    Type: Application
    Filed: November 20, 2015
    Publication date: November 9, 2017
    Inventors: Patrik Verstreken, Vanessa Morais Epifânio, Melissa Vos
  • Publication number: 20170319611
    Abstract: Disclosed are methods of treating viral infections or disorders of uncontrolled proliferation comprising, in one aspect, administering compounds that are phospholipase D inhibitors and/or Akt therapeutic agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 9, 2017
    Inventors: H. Alex Brown, Craig W. Lindsley
  • Publication number: 20170319612
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Application
    Filed: June 13, 2012
    Publication date: November 9, 2017
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Publication number: 20170319613
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: March 3, 2017
    Publication date: November 9, 2017
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20170319614
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Application
    Filed: November 16, 2015
    Publication date: November 9, 2017
    Inventors: Markus HOSSBACH, Monika KRAMPERT, Hans-Lothar ARTH
  • Publication number: 20170319615
    Abstract: Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is the use of HS8 in repair and regeneration of the skin for treating wounds, burns, ulcers and other skin injuries.
    Type: Application
    Filed: November 19, 2015
    Publication date: November 9, 2017
    Inventors: Simon Cool, Victor Nurcombe
  • Publication number: 20170319616
    Abstract: The invention provides a composition comprising glucomannan, carrageenan, xanthan gum and a monovalent or divalent cation salt. The composition is suitable for use in managing weight, combating obesity, combating metabolic syndrome, promoting satiety, reducing appetite, combating diabetes, lowering blood cholesterol, lowering blood pressure, reducing postpranial glycaemia, or increasing insulin sensitivity.
    Type: Application
    Filed: November 26, 2015
    Publication date: November 9, 2017
    Inventors: Yee Mae LIM, Pui Ee WONG, Min Pau TAN
  • Publication number: 20170319617
    Abstract: A composition for use in the treatment of a condition or disorder related to mucosal barrier dysfunction in the gut, the composition comprising activated carbon. The condition may be, for example, pouchitis or proctitis.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 9, 2017
    Applicant: FERRING B.V.
    Inventor: Mats Ekelund
  • Publication number: 20170319618
    Abstract: To provide an agent for hypodermic injection that is unlikely to cause inflammation and to provide an injector containing the agent for hypodermic injection. There is provided a method for producing an agent for hypodermic injection, wherein the agent includes a hydrogel containing sintered hydroxyapatite particles, and the production method includes a deaeration step for removing air contained in the agent.
    Type: Application
    Filed: September 14, 2015
    Publication date: November 9, 2017
    Applicant: Motejo Ltd.
    Inventor: Atsushi Kanauchi
  • Publication number: 20170319619
    Abstract: The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 9, 2017
    Applicant: Universitatsklinikum Heidelberg
    Inventors: Peter TERNESS, Gerhard OPELZ, Helmut SIMON, Sandra EHSER, Christian KLEIST, Flavius SANDRA-PETRESCU, Mircea IANCU, Lucian JIGA, Jing-Jing CHUANG, Thilo OELERT
  • Publication number: 20170319620
    Abstract: Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.
    Type: Application
    Filed: July 21, 2017
    Publication date: November 9, 2017
    Applicant: Orbis Health Solutions LLC
    Inventor: Thomas E. Wagner
  • Publication number: 20170319621
    Abstract: The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4(+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.
    Type: Application
    Filed: November 25, 2015
    Publication date: November 9, 2017
    Applicants: GREEN CROSS LAB CELL CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Bo Kyung MIN, Hana CHOI, Yu Kyeong HWANG
  • Publication number: 20170319622
    Abstract: The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios.
    Type: Application
    Filed: June 26, 2017
    Publication date: November 9, 2017
    Inventors: Christopher Gregory Taylor, Erik John Woods
  • Publication number: 20170319623
    Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.
    Type: Application
    Filed: December 19, 2016
    Publication date: November 9, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Keith D. Crawford, Christopher Southgate
  • Publication number: 20170319624
    Abstract: In some aspects, the invention relates to populations of hematopoietic cells that are enriched in PTP?? cells and methods of use thereof.
    Type: Application
    Filed: November 20, 2015
    Publication date: November 9, 2017
    Inventor: John P. Chute
  • Publication number: 20170319625
    Abstract: The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.
    Type: Application
    Filed: June 16, 2017
    Publication date: November 9, 2017
    Inventors: Thomas Hazel, Karl K. Johe
  • Publication number: 20170319626
    Abstract: An osteoinductive composition is provided which includes a plurality of surface demineralized fibrous bone chips. Each fibrous bone chip has a BET surface area from about 10 m2/gm to about 70 m2/gm. The osteoinductive composition can also include fully demineralized bone fibers. The osteoinductive composition including the surface demineralized fibrous bone chips with or without fully demineralized bone fibers can be placed in a covering, such as a mesh bag. The osteoinductive composition can include other bone structures and/or bioactive agents and/or ceramics. A method of treating a bone cavity in a patient in need thereof with the osteoinductive composition including a plurality of surface demineralized fibrous bone chips with or without fully demineralized bone fibers is also provided.
    Type: Application
    Filed: May 9, 2016
    Publication date: November 9, 2017
    Inventor: Guobao Wei